A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Exelixis
Exelixis
AstraZeneca
Precision Biotech Taiwan Corp.
Astellas Pharma Inc
Alpha Biopharma (Jiangsu) Co., Ltd.
Thomas Jefferson University
Pfizer
Spanish Lung Cancer Group
National Cancer Institute (NCI)
BerGenBio ASA
University of Utah
Astellas Pharma Inc
National Institutes of Health Clinical Center (CC)
AstraZeneca
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Hospital Israelita Albert Einstein
Canadian Cancer Trials Group
Eisai Inc.
Boehringer Ingelheim
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC
ETOP IBCSG Partners Foundation
Fox Chase Cancer Center
Spanish Lung Cancer Group
SCRI Development Innovations, LLC
M.D. Anderson Cancer Center
University of California, Davis
Bristol-Myers Squibb
M.D. Anderson Cancer Center
Daiichi Sankyo
Daiichi Sankyo
Bristol-Myers Squibb
Spectrum Pharmaceuticals, Inc
University of Texas Southwestern Medical Center
Genentech, Inc.
Intergroupe Francophone de Cancerologie Thoracique
Novartis
Odense University Hospital
Dutch Society of Physicians for Pulmonology and Tuberculosis
Albert Einstein College of Medicine
University of Texas Southwestern Medical Center
Case Comprehensive Cancer Center
Daiichi Sankyo
Ottawa Hospital Research Institute
Hoffmann-La Roche
Dana-Farber Cancer Institute
SWOG Cancer Research Network
SWOG Cancer Research Network
SWOG Cancer Research Network